Alessandro Riva
Chairman & Chief Executive Officer Transgene
Seminars
Wednesday 2nd December 2026
Mutational Landscape of Patients Treated With TG4050, an Individualized Neoantigen Therapeutic Vaccine In Early-Stage Cancer Treatment
1:30 pm
- Phase 1 study of a viral-vectored individualized neoantigen vaccine in HNSCC
- Dive deeper into the mutational landscape of the patient population and factors influencing vaccine composition
- Immunogenicity of vaccine neoantigens and potential validation of bioinformatic prediction approach
